Showing 1- [1] of [1] Publications
Author: | Julie K Wilson | |
Pubmed ID: | 29661225 | |
Journal: | Crit Care | |
Title: | Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. | |
Application: | ||
  | ||
Species: | human |
Images See all
Sample Type | Average | Range |
---|---|---|
Human plasma | 94% | 74%-125% |
Cell culture supernatants | 105% | 87%-127% |
Cell lysates | 100% | 74%-126% |
Sample | n | mean (ng/mL) | SD | CV% |
---|---|---|---|---|
1 | 20 | 8.26 | 0.64 | 7.8 |
2 | 20 | 2.02 | 0.14 | 6.8 |
3 | 20 | 0.49 | 0.02 | 4.6 |
Sample | n | mean (ng/mL) | SD | CV% |
---|---|---|---|---|
1 | 24 | 7.43 | 0.38 | 5.1 |
2 | 24 | 1.90 | 0.12 | 6.1 |
3 | 24 | 0.47 | 0.03 | 7.0 |
PD-L1 (programmed cell death ligand 1, also known as CD274 or B7-H1) is a 290 aa type I transmembrane protein. PD-L1 is expressed constitutively on murine T cells, B cells, DCs, macrophages, mesenchymal stem cells and cultured bone marrow-derived mast cells. In addition, PD-L1 is also expressed on many nonhematopoietic cell types, including vascular endothelial cells, epithelial cells, muscle cells, hepatocytes, pancreatic islet cells, astrocytes in the brain, placental syncytiotrophoblasts, and cells in cornea, iris-ciliary body and retina of eye. PD-L1 is frequently upregulated in a wide variety of solid tumors, including melanoma, ovarian, lung, glioblastoma, breast, and pancreatic cancers. PD-L1 and PD-L2 are two ligands of PD-1. Engagement of PD-1 by PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function. It is critical for the regulation of T cell function during tolerance, autoimmunity and infection.